Current HIV/AIDS Reports

, Volume 9, Issue 2, pp 121–131 | Cite as

Eliminating the HIV Reservoir

Antiretroviral Therapies (A Pozniak, Section Editor)


In the past few years, major advances have been achieved in understanding the nature and the maintenance mechanisms of the HIV reservoir. Although antiretroviral therapy works well in a majority of patients, it faces problems of compliance, resistance, toxicity, and cost. In most cases, the remaining HIV reservoir precluding antiretroviral cessation consists of a tiny cell pool that is long-lived and inaccessible to current therapies. New strategies are therefore needed to either purge or control this residual reservoir and finally stop antiretroviral drugs. Both ways leading to a functional or a sterilizing cure are currently pursued. Several molecules have been identified to achieve these goals and some of them have already entered clinical testing in humans. In this article, we review recent findings on the biology of HIV persistence and detail how HIV eradication trials should be designed in the near future.


HIV reservoirs HIV cure HIV eradication Towards HIV cure HIV persistence HIV curative strategies HIV gene therapy HIV sanctuaries Histone deacetylase inhibitors Zinc-finger nucleases HIV functional cure HIV sterilizing cure HIV remission 



A. Lafeuillade: speakers’ bureau for ViiV Healthcare.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Annals Intern Med. 2011;154:766–71.Google Scholar
  2. 2.
    • Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–7. The first paper to call for a collaborative effort toward an HIV cure. One year later, the National Institutes of Health launched a specific budget line for a cure and named it after the third author of the paper, an activist who died in 2009.PubMedCrossRefGoogle Scholar
  3. 3.
    Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remission for HIV-infected individuals. Science. 2010;329:174–80.PubMedCrossRefGoogle Scholar
  4. 4.
    •• Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Med. 2009;15:893–901. The first work describing the nature of the HIV reservoir among different CD4 subsets and demonstrating that two mechanisms are at play in the maintenance of these reservoirs.PubMedCrossRefGoogle Scholar
  5. 5.
    Redel L, Le Douce V, Cherrier T, et al. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol. 2010;87:575–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Cobos-Jiménez V, Booiman T, Hamann J, Kootstra NA. Macrophages and HIV-1. Curr Opin HIV AIDS. 2011;6:385–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother. 2011;55:3696–702.PubMedCrossRefGoogle Scholar
  8. 8.
    •• Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med. 2010;16:446–51. First demonstration that HIV can induce a latent infection in hematopoietic progenitor cells both in vitro and in vivo.PubMedCrossRefGoogle Scholar
  9. 9.
    Carter CC, McNamara LA, Onafuwa-Nuga A, et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe. 2011;9:223–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Trono D, Marzetta F. Profaning the ultimate sanctuary: HIV latency in hematopoietic stem cells. Cell Host Microbe. 2011;9:170–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Palmer S. Characterizing latent HIV reservoirs. Paper presented at the 5th International Workshop on HIV Persistence, Reservoirs and Eradication Strategies. St Maarten, West Indies: December 6-9, 2011. Global Antiviral Journal 2011;7(suppl 2):11-12. Available at
  12. 12.
    Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol. 2009;83:8470–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol. 2011;85:5220–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Lerner P, Guadalupe M, Donovan R, et al. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol. 2011;85:4772–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Sharkey M, Babic DZ, Greenough T, et al. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011;7:e1001303.PubMedCrossRefGoogle Scholar
  18. 18.
    Josefsson L, Dahl V, Palmer S. Can HIV infection be eradicated through use of potent antiviral agents? Curr Opin Infect Dis. 2010;23:628–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Maldarelli F. Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS. 2010;6:49–56.CrossRefGoogle Scholar
  20. 20.
    McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203:960–8.PubMedCrossRefGoogle Scholar
  22. 22.
    • Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification on HAART-suppressed subjects. Nature Med. 2010;16:460–5. This trial shows that beyond residual plasma viremia, more sensitive markers can detect changes during raltegravir intensification, proving that ongoing replication exists in some patients.PubMedCrossRefGoogle Scholar
  23. 23.
    Kovacs C, Brunetta J, Chun TW, et al. Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in gut associated lymphoid tissue (GALT): a randomized, placebo controlled trial [abstract MOAA0103]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17–20, 2011.Google Scholar
  24. 24.
    • Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451–60. Although the sample size is limited to seven patients, it is the only study analyzing the effect of raltegravir intensification on gut-associated lymphoid tissue at different levels: ileum, colon, rectum.PubMedCrossRefGoogle Scholar
  25. 25.
    Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202:1553–61.PubMedCrossRefGoogle Scholar
  26. 26.
    • Smurzynski M, Wu K, Letendre S, et al. Effect of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357–65. This study shows that the use of antiretroviral drugs with better central nervous system penetration might be associated with better neurocognitive functioning.PubMedCrossRefGoogle Scholar
  27. 27.
    Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Shen L, Siliciano RF. Achieving a quantitative understanding of antiretroviral drug efficacy. Clin Infect Dis. 2010;51:1105–6.PubMedCrossRefGoogle Scholar
  29. 29.
    • Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011;477:95–8. Although it was already established that cell-to-cell HIV spread occurs at the virological synapse, this study shows that it is a mechanism of ongoing viral propagation and resistance to ART.PubMedCrossRefGoogle Scholar
  30. 30.
    Schacker T, Stevenson M, Fletcher C. Anatomic HIV reservoirs. Paper presented at the 5th International Workshop on HIV Persistence, Reservoirs and Eradication Strategies. St Maarten, West Indies: December 6–9, 2011. Global Antiviral Journal 2011;7(suppl 2):28–29. Available at
  31. 31.
    • Cohen J. Tissue says blood is misleading, confusing HIV cure efforts. Science. 2011;334:1614. The article shows graphs correlating the absence of antiretrovirals at sufficient concentrations in lymphoid tissues to the persistence of HIV in these tissues.PubMedCrossRefGoogle Scholar
  32. 32.
    Rong L, Perelson AS. Asymetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci. 2009;217:77–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sekaly RP. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011;6:30–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Vandergeeten C, Da Fonseca S, Sereti I, et al. Differential impact of IL-7 and IL-15 on HIV reservoir persistence [abstract MOAA0101]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17–20, 2011.Google Scholar
  35. 35.
    Lewis MG, DaFonseca S, Chomont N, et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011;25:1347–56.PubMedCrossRefGoogle Scholar
  36. 36.
    Szeto GL, Brice AK, Yang HC, et al. Minocyclin Attenuated HIV Infection and Reactivation by Suppressing Cellular Activation in Human CD4+ T Cells. J Infect Dis. 2010;201:1132–40.PubMedCrossRefGoogle Scholar
  37. 37.
    DaFonseca S, Chomont N, El Far M, et al. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway persistence [abstract 268]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27–Mar 2, 2011.Google Scholar
  38. 38.
    Porichis F, Kwon DS, Zupkosky J, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118:965–74.PubMedCrossRefGoogle Scholar
  39. 39.
    Chomont N. New concept in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference [abstract WESY0101]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17–20, 2011.Google Scholar
  40. 40.
    Lewin S. Contribution of the immune system to HIV persistence. [abstract WEWS0303]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17–20, 2011.Google Scholar
  41. 41.
    Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS. 2011;25:741–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Boasso A. Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis. Curr Med Chem. 2011;18:2247–56.PubMedGoogle Scholar
  44. 44.
    Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2:32ra36.PubMedCrossRefGoogle Scholar
  45. 45.
    Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J infect Dis. 2008;197:126–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV infection. AIDS. 2010;24:1598–15601.PubMedCrossRefGoogle Scholar
  48. 48.
    Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011;25:885–97.PubMedCrossRefGoogle Scholar
  49. 49.
    Lafeuillade A. Potential strategies for an HIV infection cure. HIV Clin Trials. 2011;12:121–30.PubMedCrossRefGoogle Scholar
  50. 50.
    •• Pandrea I, Gaufin T, Gautam R, et al. Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T cells and Is Reverted by CD8+ Cell Depletion. PLoS Pathog. 2011;7:e1002170. A new animal model of elite control of lentiviral infection is described in which control occurs in 100% of cases. It allows the study of virological and immunological events that may lead to the infection control both in blood and tissues.PubMedCrossRefGoogle Scholar
  51. 51.
    •• Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–8. The first report of the “Berlin patient” who received two bone marrow transplants to cure a relapsing leukemia.PubMedCrossRefGoogle Scholar
  52. 52.
    •• Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011;117:2791–9. The final report of the “Berlin patient” where the word “cure” is used.PubMedCrossRefGoogle Scholar
  53. 53.
    Hütter G, Thiel E. Allogenic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no.2. AIDS. 2011;25:273–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Quan Y, Liang C, Brenner BG, Wainberg MA. Multidrug-Resistant Variants of HIV Type 1 (HIV-1) Can Exist in cells as Defective Quasispecies and Be rescued by superinfection with Other Defective HIV-1 Variants. J Infect Dis. 2009;200:1479–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Liszewski MK, Yu JJ, O’Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009;47:254–60.PubMedCrossRefGoogle Scholar
  56. 56.
    Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbour low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV + patients on and off ART. PLoS Pathog. 2011;7:e1001300.PubMedCrossRefGoogle Scholar
  57. 57.
    Agosto LM, Liszewski MK, Mexas A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology. 2011;409:46–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Schacker T. New tools to track HIV. Nat Med. 2010;16:373–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Richman DD. Challenges to finding a cure for HIV infection. Curr Opin HIV AIDS. 2011;6:1–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implication for eradication. AIDS. 2010;24:2803–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Iglesias-Ussel MD, Romerio F. HIV reservoirs: the new frontier. AIDS Rev. 2011;13:13–29.PubMedGoogle Scholar
  62. 62.
    Avettand-Fenoel V, Prazuck T, Hocqueloux L, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS. 2008;22:1880–2.PubMedCrossRefGoogle Scholar
  63. 63.
    Li Q, Skinner PJ, Duan L, Haase AT. A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ. J Vis Exp. 2009;30. pii:1561.Google Scholar
  64. 64.
    Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985–9.PubMedCrossRefGoogle Scholar
  65. 65.
    • McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;1:11–23. A complete description of our current understanding of early immunological events at acute HIV infection.CrossRefGoogle Scholar
  66. 66.
    • Engel ME, Hiebert SW. The enemy within: dormant retroviruses awaken. Nat Med. 2010;16:517–8. One hundred million years ago the genome of the first mammals was attacked by retroviruses. Currently, 8% of the human genome still contain these repressed retroviral sequences which are regulated by the same mechanisms as HIV.PubMedCrossRefGoogle Scholar
  67. 67.
    Schleifman EB, Bindra R, Leif J, et al. Targeted Disruption of the CCR5 Gene in Human Hematopoietic Stem Cells Stimulated by Peptide Nucleic Acids. Chem Biol. 2011;18:1189–98.PubMedCrossRefGoogle Scholar
  68. 68.
    • Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25:577–80. According to these authors, reactivating HIV from latency with current antiretroviral drugs unable to reach correctly the central nervous system could have devastating effects on the brain.PubMedCrossRefGoogle Scholar
  69. 69.
    • Ananworanich J, Schetz A, Sereti A, et al. Mega-HAART suppresses HIV viremia, reduces viral reservoir, and restores immunity in peripheral blood and sigmoid colon of acute HIV-infected subjects [abstract 516]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27–Mar 2, 2011. In this pilot study, 20 Thais with acute infection received a combination of tenofovir, emtricitabine, efavirenz, raltegravir, and maraviroc. A strong antiviral effect was observed together with a restoration of CD4+ cells in blood and gut. This trial is ongoing and now randomized between three versus five drugs for 6 months with a three-drug regimen beyond 6 months. Google Scholar
  70. 70.
    • Markowitz M, Evering T, Caskey M, et al. A randomized open-label trial of 5-drug vs 3-drug standard PI-based cART initiated during acute and early HIV-1 infection: 48-weeks results [abstract 148LB]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27–Mar 2, 2011. This study randomized 40 patients between regimens containing three or five antiretrovirals. No virologic or immunologic benefit was demonstrated for the five-drug regimen. However, this trial included both acutely infected cases and cases with early infection. Google Scholar
  71. 71.
    Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009;6:III.CrossRefGoogle Scholar
  72. 72.
    Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbial. 2009;7:798–812.CrossRefGoogle Scholar
  73. 73.
    Keedy KS, Kashuba AD, Margolis DM. Therapy for persistent HIV. Trends Pharmacol Sci. 2010;31:206–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med. 2009;11:e6.PubMedCrossRefGoogle Scholar
  75. 75.
    Choudhary SK, Margolis DM. Curing HIV: pharmacologic approaches to target HIV-1 latency. Ann Rev Pharmacol Toxicol. 2011;51:397–418.CrossRefGoogle Scholar
  76. 76.
    Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep. 2010;7:37–43.PubMedCrossRefGoogle Scholar
  77. 77.
    Margolis DM. Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retroviruses. 2011;4:347–53.CrossRefGoogle Scholar
  78. 78.
    Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011;6:25–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med. 2011;17:466–72.PubMedCrossRefGoogle Scholar
  80. 80.
    Choi BS, Lee HS, Oh YT, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS. 2010;24:609–11.PubMedCrossRefGoogle Scholar
  81. 81.
    Cohen J. The emerging race to cure HIV infections. Science. 2011;332:787–9.CrossRefGoogle Scholar
  82. 82.
    Perez M, de Vinuesa AG, Sanchez-Duffhues G, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 2010;8:418–29.PubMedCrossRefGoogle Scholar
  83. 83.
    Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS ONE. 2011;6:e18270.PubMedCrossRefGoogle Scholar
  84. 84.
    Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol. 2010;84:5958–74.PubMedCrossRefGoogle Scholar
  85. 85.
    Wang FX, Xu Y, Sullivan J, Souder E, et al. IL-7 is a potent and proviral-strain specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest. 2005;115:128–37.PubMedGoogle Scholar
  86. 86.
    • Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog. 2011;7:e1002288. In this model, the strong effect of IL-7 on the proliferation of memory cells counteracts its modest ability to purge latent viruses.PubMedCrossRefGoogle Scholar
  87. 87.
    • Imamichi H, DeGray G, Asmuth DM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011;25:159–64. Recombinant IL-7 produced viral blips in seven ART-controlled patients following a single-dose administration, but no change in quasispecies indicative of an impact on silent viral sources.PubMedCrossRefGoogle Scholar
  88. 88.
    Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol. 2011;85:6060–4.PubMedCrossRefGoogle Scholar
  89. 89.
    • Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnol. 2010;28:839–47. Hematopoietic stem/progenitor cells were successfully disrupted by zinc-finger nucleases for CCR5 expression, engrafted in a mouse model, which achieved lower levels of HIV-1 viremia.CrossRefGoogle Scholar
  90. 90.
    Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nature Biotechnol. 2010;28:807–10.CrossRefGoogle Scholar
  91. 91.
    Lalezari J, Mitsuyasu R, Deeks S, et al. Successful and persistent engraftment of ZFN-M-R5-D autologous CD4 T Cells (SB-728-T) in aviremic HIV-infected subjects on HAART [abstract 46]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27–Mar 2, 2011.Google Scholar
  92. 92.
    Tebas P, Levine B, Binder G, et al. Disruption of CCR5 in zinc finger nuclease treated CD4 T cells: phase I trials [abstract 165]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27–Mar 2, 2011.Google Scholar
  93. 93.
    Ando D, Tang WW, Stein D, June C, et al. HAART Treatment Interruption following Adoptive Transfer of Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load [abstract H2-794a]. Paper presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL: 17–20 September, 2011.Google Scholar
  94. 94.
    McNeer NA, Chin JY, Schleifman EB, et al. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther. 2011;1:172–80.CrossRefGoogle Scholar
  95. 95.
    DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci transl Med. 2010;2:36ra43.PubMedCrossRefGoogle Scholar
  96. 96.
    Lunzen J, Fehse B, Hauber J. Gene therapy strategies: can we eradicate HIV? Curr HIV/AIDS Rep. 2011;8:78–84.PubMedCrossRefGoogle Scholar
  97. 97.
    Levin A, Hayouka Z, Friedler A, Loyter A. Specific eradication of HIV-1 from infected cultured cells. AIDS Res Ther. 2010;7:31.PubMedCrossRefGoogle Scholar
  98. 98.
    Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog. 2010;6:e1000803.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Chief Department of Infectious DiseasesGeneral HospitalToulonFrance

Personalised recommendations